Ophthalmoplegia Market Information: By Types (External Opthalmoplegia, Internuclear Opthalmoplegia), By Treatment (Surgery, Drug Treatment), By End Users (Hospital & Clinics, Ambulatory Clinics) - Forecast Till 2027
Market Highlights Ophthalmoplegia refers to the condition of double or blurred vision due to damage of the ophthalmic nerves. It can be caused by congenital abnormalities, trauma, viral infections, or disorders that affect the nervous system including multiple sclerosis, cerebral tumors, and migraines. Diabetes is one of the major cause of ophthalmoplegia. Increasing prevalence of ophthalmoplegia, increasing geriatric population, and changing lifestyle are the major driver for the growth of the market. Moreover, increasing prevalence of diabetes & other neurological diseases, and increasing government support for research & development have fuelled the market growth. However, high cost of the treatment may hinder the growth of the market over the assessment period.
The global ophthalmoplegia market is expected to grow at a CAGR of ~ 7.2 % during the forecast period 2017-2023.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4216
Key Players
Some of key players profiled in the report are Abbott (US), Novartis AG (Switzerland), ZEISS International (Germany), Valeant Pharmaceuticals International, Inc. (US), Amritt, Inc. (US), Medline Industries, Inc. (US), ALLERGAN (Ireland), and Johnson & Johnson (US).
Segments: The global ophthalmoplegia market has been segmented on the basis of type, treatment and end user.
On the basis of types, the market is segmented into external ophthalmoplegia and internuclear ophthalmoplegia. External ophthalmoplegia is further segmented into superior recti, inferior recti, medial recti, lateral recti, inferior oblique, and superior oblique muscles.
On the basis of treatment, the market is segmented into surgery, drug treatment, and others. The surgery is further segmented into strabismus surgery and others.
On the basis of end users, the market is segmented into hospital & clinics, ambulatory clinics, and others.
Regional analysis:
The Americas dominates the global ophthalmoplegia market owing to well-developed technology and increased patient population with eye sight problem primarily due to increasing prevalence of diabetes. Additionally, high healthcare expenditure and the presence of some of the leading players have fuelled the growth of the market in this region.
Europe is the second largest ophthalmoplegia market, which is followed by Asia Pacific. Increasing government support and availability of funds for research drive the growth of the market. Asia Pacific is the fastest growing ophthalmoplegia market due to increasing geriatric population and rapidly developing medical sector.
On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities and poor economic and political conditions in Africa.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Comments